3Tasaka K.Epinastine:An update of its pharmacology,metabolism,clinical efficacy and tolerability in the treatment of allergic diseases.Drugs Today (Barc),2000,36(11):735-757.
3Tasaka K.Epinastine:An update of its pharmacology,metabolism,clinical efficacy and tolerability in the treatment of allergic diseases.Drugs Today (Barc),2000,36:735-757.
4Grant JA,Danielson L,Rihoux JP,et al.A double-blind,single-dose,crossover comparison of cetirizine,ebastine,epinastine,fexofenadine,terfenadine,and loratadine versus placebo:suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.Allergy,1999,54:700-707.
5Pichat P;Angel I;Arbilla S.Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat,1998(01).
6Benavides J;Schoemaker H;Dana C.In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent,1995.
7Dubertr;Murrieta Aguttes M;Tonet J.Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria:results of the MILOR Study[J],1999.
8Sabbah A;Daele J;Wade AG.Comparison of the efficacy,safety,and onset of action of mizolastine,cetirizine,and placebo in the management of seasonal allergic rhinoconjunctivitis.MIZOCET Study Group[J],1999.
9Leynadier F;Duarte-Risselin C;Murrieta M.Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria URTILOR study group,2000.
